Syndax Pharmaceuticals, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2016-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2016-09-30 was $0.00.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2016-06-30 was $0.00.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2016-03-31 was $321.71M.
- Syndax Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2016 was $321.71M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $321.71M 10-K · filed 2019-03-07 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | |
| 2016-03-31 | $321.71M 10-Q · filed 2016-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |